Carbamazepine derivatives with P2X4 receptor-blocking activity.

Article Details

Citation
Copy to clipboard

Tian M, Abdelrahman A, Weinhausen S, Hinz S, Weyer S, Dosa S, El-Tayeb A, Muller CE

Carbamazepine derivatives with P2X4 receptor-blocking activity.

Bioorg Med Chem. 2014 Feb 1;22(3):1077-88. doi: 10.1016/j.bmc.2013.12.035. Epub 2013 Dec 25.

PubMed ID
24411477 [ View in PubMed
]
Abstract

Antagonists for the P2 receptor subtype P2X4, an ATP-activated cation channel receptor, have potential as novel drugs for the treatment of neuropathic pain and other inflammatory diseases. In the present study, a series of 47 carbamazepine derivatives including 32 novel compounds were designed, synthesized, and evaluated as P2X4 receptor antagonists. Their potency to inhibit ATP-induced calcium influx in 1321N1 astrocytoma cells stably transfected with the human P2X4 receptor was determined. Additionally, species selectivity (human, rat, mouse) and receptor subtype selectivity (P2X4 vs P2X1, 2, 3, 7) were investigated for selected derivatives. The most potent compound of the present series, which exhibited an allosteric mechanism of P2X4 inhibition, was N,N-diisopropyl-5H-dibenz[b,f]azepine-5-carboxamide (34, IC50 of 3.44muM). The present study extends the so far very limited knowledge on structure-activity relationships of P2X4 receptor antagonists.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
EslicarbazepineP2X purinoceptor 4ProteinHumans
Yes
Not AvailableDetails
Eslicarbazepine acetateP2X purinoceptor 4ProteinHumans
Yes
Antagonist
Details